Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity

Authors

• Ofer Zimmerman, Washington University School of Medicine in St. Louis
• Alexa Michelle Altman Doss, Washington University School of Medicine in St. Louis
• Baoling Ying, Washington University School of Medicine in St. Louis
• Chieh-Yu Liang, Washington University School of Medicine in St. Louis
• Samantha R. Mackin, Washington University School of Medicine in St. Louis
• Hannah G. Davis-Adams, Washington University School of Medicine in St. Louis
• Lucas J. Adams, Washington University School of Medicine in St. Louis
• Laura A. VanBlargan, Washington University School of Medicine in St. Louis
• Rita E. Chen, Washington University School of Medicine in St. Louis
• Suzanne M. Scheaffer, Washington University School of Medicine in St. Louis
• Pritesh Desai, Washington University School of Medicine in St. Louis
• Saravanan Raju, Washington University School of Medicine in St. Louis
• Tarisa L. Mantia, Washington University School of Medicine in St. Louis
• Caitlin C. O'Shaughnessy, Washington University School of Medicine in St. Louis
• Jennifer Marie Monroy, Washington University School of Medicine in St. Louis
• H. James Wedner, Washington University School of Medicine in St. Louis
• Christopher J. Rigell, Washington University School of Medicine in St. Louis
• Andrew L. Kau, Washington University School of Medicine in St. Louis
• Tiffany Biason Dy, Washington University School of Medicine in St. Louis
• Zhen Ren, Washington University School of Medicine in St. Louis
• Jackson S. Turner, Washington University School of Medicine in St. Louis
• Jane A. O'Halloran, Washington University School of Medicine in St. Louis
• Rachel M. Presti, Washington University School of Medicine in St. Louis
• Peggy L. Kendall, Washington University School of Medicine in St. Louis
• Daved H. Fremont, Washington University School of Medicine in St. Louis
• Ali H. Ellebedy, Washington University School of Medicine in St. Louis
• Michael S Diamond, Washington University School of Medicine in St. Louis

Journal

JCI Insight

Publication Date

2-8-2024

Volume

9

Issue

3

First Page

e176359

Document Type

Open Access Publication

DOI

10.1172/jci.insight.176359

Rights and Permissions

Zimmerman O, Altman Doss AM, Ying B, Liang CY, Mackin SR, Davis-Adams HG, Adams LJ, VanBlargan LA, Chen RE, Scheaffer SM, Desai P, Raju S, Mantia TL, O'Shaughnessy CC, Monroy JM, Wedner HJ, Rigell CJ, Kau AL, Dy TB, Ren Z, Turner JS, O'Halloran JA, Presti RM, Kendall PL, Fremont DH, Ellebedy AH, Diamond MS. Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity. JCI Insight. 2024 Feb 8;9(3):e176359. doi: 10.1172/jci.insight.176359. © 2024, Zimmerman et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License

Recommended Citation

Zimmerman, Ofer; Altman Doss, Alexa Michelle; Ying, Baoling; Liang, Chieh-Yu; Mackin, Samantha R.; Davis-Adams, Hannah G.; Adams, Lucas J.; VanBlargan, Laura A.; Chen, Rita E.; Scheaffer, Suzanne M.; Desai, Pritesh; Raju, Saravanan; Mantia, Tarisa L.; O'Shaughnessy, Caitlin C.; Monroy, Jennifer Marie; Wedner, H. James; Rigell, Christopher J.; Kau, Andrew L.; Dy, Tiffany Biason; Ren, Zhen; Turner, Jackson S.; O'Halloran, Jane A.; Presti, Rachel M.; Kendall, Peggy L.; Fremont, Daved H.; Ellebedy, Ali H.; and Diamond, Michael S, "Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity." JCI Insight. 9, 3. e176359 (2024).
https://digitalcommons.wustl.edu/oa_4/3295

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.